摘要 |
The present invention provides novel highly sialylated Fc-EPO fusion proteins preferably comprising a couple of modifications in the Fc- portion as well as in the EPO portion and having improved pharmacokinetics. Specifically, the Fc-EPO proteins have a prolonged serum half-life and increased in vivo potency. The Fc-EPO fusion proteins synthesized in BHK cells have dramatically prolonged serum half-lives and increased in vivo potency when compared to corresponding Fc-EPO fusion proteins produced in other cell lines, such as, for example, NS/O cells. |